Keyword Suggestion
Domain Informations
Orsiro.com lookup results from whois.corehub.net server:
- Domain created: 2009-12-21T15:48:09Z
- Domain updated: 2023-12-21T00:09:11Z
- Domain expires: 2024-12-21T15:48:09Z 0 Years, 47 Days left
- Website age: 14 Years, 318 Days
- Registrar Domain ID: 1579558695_DOMAIN_COM-VRSN
- Registrar Url: http://corehub.net
- Registrar WHOIS Server: whois.corehub.net
- Registrar Abuse Contact Email: [email protected]
- Registrar Abuse Contact Phone: +34935275235
- Name server:
- NS01.VERSATEL.DE
- NS02.VERSATEL.DE
- NS03.VERSATEL.DE
| Domain Provider | Number Of Domains |
|---|---|
| godaddy.com | 286730 |
| namecheap.com | 101387 |
| networksolutions.com | 69118 |
| tucows.com | 52617 |
| publicdomainregistry.com | 39120 |
| whois.godaddy.com | 32793 |
| enomdomains.com | 23825 |
| namesilo.com | 21429 |
| domains.google.com | 21384 |
| cloudflare.com | 20573 |
| gmo.jp | 18110 |
| name.com | 17601 |
| fastdomain.com | 14708 |
| register.com | 13495 |
| net.cn | 12481 |
| ionos.com | 12416 |
| ovh.com | 12416 |
| gandi.net | 12305 |
| registrar.amazon.com | 12111 |
Host Informations
- IP address: 91.204.11.39
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
Site Inspections
Port Scanner (IP: 91.204.11.39)
Spam Check (IP: 91.204.11.39)
Recent Searched Sites
› Kuroshioichiba.co.jp (21 seconds ago) / JP
› Nullfurniture.com (41 seconds ago) / US
› Shop.farirteb.com (6 seconds ago) / IR
› Shejicloud.com (45 seconds ago) / CN
› Lil.no (2 seconds ago) / NO
› Awakzon.com (1 seconds ago) / CN
› Balkanjizz.com (3 seconds ago) / US
› Ibis-budget-aracaju-hotel.hotels-aracaju.com (12 seconds ago) / DE
› Asiapornvids.com (10 seconds ago) / US
› Orsiro.com (0 seconds ago) / DE
› Espaceigt.ancfcc.gov.ma (10 seconds ago) / IE
› Hits4all.com (19 seconds ago) / GB
› Unade.edu.mx (4 seconds ago) / CA
› Booru.allthefallen.moe (42 seconds ago) / US
› Lucitediakon.com (1 seconds ago) / US
› Thetopdirectory.com (6 seconds ago) / US
› Mikatogo.com (15 seconds ago) / US
› Esc-production-2021.s3.eu-west-2.amazonaws.com (44 seconds ago) / GB
› Travisaroy.com (46 seconds ago) / US
› 1024xp.com (40 seconds ago) / US
Websites Listing
We found Websites Listing below when search with orsiro.com on Search Engine
Contact | Orsiro
Thank you for getting in touch with us! Please contact us using the form below and a BIOTRONIK team member will respond shortly. Please find our international BIOTRONIK contacts here.
En.orsiro.comHome | Orsiro
The safety and effectiveness of Orsiro and Orsiro Mission have not yet been established in patients with the following: In-stent restenosis. 3 vessel coronary disease. An unresolved thrombus at the lesion site. Coronary artery reference …
En.orsiro.comContact | Orsiro US
BIOTRONIK, Inc. 6024 Jean Road Lake Oswego, OR 97035-5369 (800) 547-0394 (24-hour) (800) 291-0470
Us.orsiro.comBIOSTEMI 2Y | Orsiro
The safety and effectiveness of Orsiro and Orsiro Mission have not yet been established in patients with the following: In-stent restenosis. 3 vessel coronary disease. An unresolved thrombus at the lesion site. Coronary artery reference …
En.orsiro.comOrsiro - Biotronik
Email address. Phone. Country/Region . Country/Region. Your message ... 5 Jensen et al. Randomized comparison of a sirolimus-eluting Orsiro stent with a biolimus-eluting Nobori stent in patients treated with percutaneous coronary …
Biotronik.comConclusions - en.orsiro.com
Clinical data conducted with Orsiro, Orsiro Mission’s predecessor device can be used to illustrate Orsiro Mission clinical outcomes. Meta-analysis Full Cohort Randomized comparison of Ultrathin Strut Orsiro with Xience Prime. All-comers results out to 5 years Vascular Intervention // Coronary // Orsiro Conclusions • In this 2,119 patient, randomized, all-comers trial, Orsiro® ...
En.orsiro.comOrsiro – BIOSCIENCE
Orsiro – BIOSCIENCE 2,119 Patients with stable CAD or ACS undergoing PCI Orsiro n = 1,063 1-month clinical follow-up Xience Prime n = 1,056 12-month clinical follow-up* Conclusions In this 2,119 patient, randomized, all-comers trial, Orsiro demonstrated non-inferiority to Xience Prime for the primary endpoint at 12 months. A similar trend was shown throughout 24 months …
Biotronik.cdn.mediamid.comNEWSROOM | Orsiro US
Home Orsiro Mission DES Orsiro DES CLINICAL STUDIES NEWSROOM Contact EN Please select a country/region and language. Countries/Regions. United States of America; Languages. Confirm your selection. Search. Submit. NEWS ROOM HOME; PRESS RELEASES AND STATEMENTS; STORIES; Press Contact . Dr. Zara Barlas. Corporate Public Relations & …
Us.orsiro.comApplication Publishing, Cloud Desktop, Server Hosting ...
Headquarters: 3580 Isabelle Street, suite 200 Brossard, Quebec, J4Y 2R3 Email: [email protected]
Oriso.comNEWSROOM | Orsiro US
Home Orsiro Mission DES Orsiro DES CLINICAL STUDIES NEWSROOM Contact EN Please select a country/region and language. Countries/Regions. United States of America; Languages. Confirm your selection. Search Submit. NEWS ROOM HOME; PRESS RELEASES AND STATEMENTS; STORIES; Press Contact . Dr. Zara Barlas. Corporate Public Relations & …
Us.orsiro.comOrsiro - Biotronik
Orsiro is superior to Xience in STEMI patients undergoing primary PCI with respect to Target Lesion Failure (TLF) rate at 12 months. Long-term safety . In the randomized, all-comers BIOSCIENCE trial (n= 2,119) 5. Orsiro shows numerically equal or lower Stent Thrombosis (ST) in complex patients in comparison to Xience. * Compared to Xience, BIOTRONIK data on file, …
Biotronik.comorsiro - GitHub
Block or report orsiro. Block user. Prevent this user from interacting with your repositories and sending you notifications. Learn more about blocking users . You must be logged in to block users. Block user. Report abuse. Contact GitHub support about this user’s behavior. Learn more about reporting abuse .
Github.comBIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years ...
2022-03-02 · March 02, 2022. Final 5-year follow-up from the BIOFLOW V trial continues to show advantages for the ultrathin-strut bioresorbable-polymer Orsiro DES (Biotronik) over the thin-strut, durable-polymer Xience (Abbott), with reductions in target-vessel MI and stent thrombosis. While rates of TLF had been lower with Orsiro versus Xience at 1, 2, and ...
Tctmd.comHeart | Orsiro US
As we get older, our risk for a variety of cardiovascular conditions increases. It’s a fact that likely doesn’t come as a big surprise to many people—but that doesn’t mean the discussions aging patients need to have with their families and doctors get any easier.
Us.orsiro.comOrsiro Mission gets CE mark - Cardiovascular News
2020-02-12 · Orsiro Mission is now available in CE mark countries. The press release outlines that the Orsiro Mission DES has a completely reengineered delivery system to support interventionalists with outstanding deliverability, even in challenging cases. The coating combines passive and active components to avoid interaction with surrounding tissue, while ensuring a …
Cardiovascularnews.comBiotronik - Laravel Nova
Email Address. Password. Remember Me. Forgot Your Password? Login Orsiropedia with Mission US CMS. Email Address. Password. Remember Me . Forgot Your Password? ...
Orsiro-mission-us.cms.biopedia.biotronik.comUltrathin Orsiro Performs Well in All-Comers, Interim ...
2021-05-24 · With imaging-guided PCI, the ultrathin-strut, biodegradable-polymer Orsiro stent (Biotronik) achieves 12-month efficacy similar to what’s offered by the durable-polymer Xience (Abbott) in a wide spectrum patients with stable and unstable CAD, interim results from the CASTLE trial suggest.. Earlier studies, such as BIOSTEMI and BIOFLOW V, have shown the …
Tctmd.comBIOTRONIK Newsroom - Newsroom BIOTRONIK
These data reinforce the body of evidence differentiating Orsiro ... For any questions, please do not hesitate to contact your local BIOTRONIK representative or email us at [email protected]. BIOTRONIK Statement on the Log4Shell Vulnerability. The vast majority of strokes—about 85 percent—are ischemic. Of these, up to a third are cryptogenic, or have no clear cause. Getting …
News.biotronik.comBIOTRONIK’s Orsiro Ultrathin Coronary Stent Approved in U ...
2019-02-25 · The two year results presented at TCT 2018 and published in the Journal of the American College of Cardiology show a 37 percent lower TLF rate in favor of Orsiro (7.5 percent versus 11.9 percent ...
Medgadget.comOrsiro - CathLab.com
Orsiro is indicated for improving coronary luminal diameter in patients, including those with diabetes mellitus, with symptomatic heart disease, stable angina, unstable angina, non-ST elevation myocardial infarction or documented silent ischemia due to atherosclerotic lesions in the native coronary arteries with a reference vessel diameter of 2.25 mm to 4.0 mm and a lesion …
Cathlab.com
Domains Expiration Date Updated
| Site | Provider | Expiration Date |
|---|---|---|
| freegate.io | godaddy.com | -2 Years, -273 Days |
| everandanonbd.com | publicdomainregistry.com | -2 Years, -224 Days |
| nevadavanadium.com | godaddy.com | -1 Years, -165 Days |
| cgyca.org | register.com | -2 Years, -234 Days |
| gridandglam.com | godaddy.com | -2 Years, -14 Days |
| getfrisch.com | godaddy.com | -1 Years, -32 Days |
| uatwb3.com | godaddy.com | -2 Years, -105 Days |
| owllify.com | name.com | -2 Years, -171 Days |
| brabos.club | whois.godaddy.com | -2 Years, -50 Days |
| googel.com | markmonitor.com | -1 Years, -285 Days |